These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 31487220

  • 21. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 22. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
    van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker PD.
    BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
    [Abstract] [Full Text] [Related]

  • 23. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer.
    Scholte M, Barentsz JO, Sedelaar JPM, Gotthardt M, Grutters JPC, Rovers MM.
    Eur Urol Focus; 2020 Sep 15; 6(5):967-974. PubMed ID: 30826284
    [Abstract] [Full Text] [Related]

  • 24. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.
    Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M.
    J Urol; 2016 May 15; 195(5):1436-1443. PubMed ID: 26682756
    [Abstract] [Full Text] [Related]

  • 25. 68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy.
    Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, Karakiewicz P, Schoerner W, Hammerer P, Schiffmann J.
    World J Urol; 2020 Dec 15; 38(12):3085-3090. PubMed ID: 32103332
    [Abstract] [Full Text] [Related]

  • 26. [18F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer.
    Alemozaffar M, Akintayo AA, Abiodun-Ojo OA, Patil D, Saeed F, Huang Y, Osunkoya AO, Goodman MM, Sanda M, Schuster DM.
    J Urol; 2020 Oct 15; 204(4):734-740. PubMed ID: 32347780
    [Abstract] [Full Text] [Related]

  • 27. Detection of pelvic lymph node metastases in patients with clinically localized prostate cancer: comparison of [18F]fluorocholine positron emission tomography-computerized tomography and laparoscopic radioisotope guided sentinel lymph node dissection.
    Häcker A, Jeschke S, Leeb K, Prammer K, Ziegerhofer J, Sega W, Langsteger W, Janetschek G.
    J Urol; 2006 Nov 15; 176(5):2014-8; discussion 2018-9. PubMed ID: 17070241
    [Abstract] [Full Text] [Related]

  • 28. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series.
    Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A.
    Eur Urol; 2020 Dec 15; 78(6):779-782. PubMed ID: 32624281
    [Abstract] [Full Text] [Related]

  • 29. Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
    Jansen BHE, Bodar YJL, Zwezerijnen GJC, Meijer D, van der Voorn JP, Nieuwenhuijzen JA, Wondergem M, Roeleveld TA, Boellaard R, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN.
    Eur J Nucl Med Mol Imaging; 2021 Feb 15; 48(2):509-520. PubMed ID: 32789599
    [Abstract] [Full Text] [Related]

  • 30. Rational use of Ga-68 PSMA PET-CT according to nomograms and risk groups for the detection of lymph node metastasis in prostate cancer.
    Madendere S, Kılıç M, Köseoğlu E, Aykanat İC, Eden AB, Coşkun B, Tekkalan FB, Balbay MD.
    Urol Oncol; 2024 Feb 15; 42(2):29.e9-29.e15. PubMed ID: 38114351
    [Abstract] [Full Text] [Related]

  • 31. 68Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study.
    Petersen LJ, Nielsen JB, Langkilde NC, Petersen A, Afshar-Oromieh A, De Souza NM, De Paepe K, Fisker RV, Arp DT, Carl J, Haberkorn U, Zacho HD.
    World J Urol; 2020 Apr 15; 38(4):939-948. PubMed ID: 31190153
    [Abstract] [Full Text] [Related]

  • 32. Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission Tomography.
    Vis AN, Meijer D, Roberts MJ, Siriwardana AR, Morton A, Yaxley JW, Samaratunga H, Emmett L, van de Ven PM, Heymans MW, Nieuwenhuijzen JA, van der Poel HG, Donswijk ML, Boellaard TN, Schoots IG, Stricker P, Haynes AM, Oprea-Lager DE, Coughlin GD, van Leeuwen PJ.
    Eur Urol Oncol; 2023 Dec 15; 6(6):553-563. PubMed ID: 37045707
    [Abstract] [Full Text] [Related]

  • 33. One-Stop-Shop Whole-Body 68Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer.
    Thalgott M, Düwel C, Rauscher I, Heck MM, Haller B, Gafita A, Gschwend JE, Schwaiger M, Maurer T, Eiber M.
    J Nucl Med; 2018 Dec 15; 59(12):1850-1856. PubMed ID: 29794224
    [Abstract] [Full Text] [Related]

  • 34. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY).
    Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Stambler N, Lin T, Jensen J, Wong V, Siegel BA, Morris MJ.
    J Urol; 2021 Jul 15; 206(1):52-61. PubMed ID: 33634707
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
    Kim SJ, Lee SW, Ha HK.
    Urol Int; 2019 Jul 15; 102(1):27-36. PubMed ID: 30269140
    [Abstract] [Full Text] [Related]

  • 38. 18 F-prostate specific membrane antigen positron emission tomography/computerized tomography for lymph node staging in medium/high risk prostate cancer: A systematic review and meta-analysis.
    Lv Z, Song L, Wang M, Hou H, Li H, Wang X, Wang J, Wang J, Liu M.
    Chin Med J (Engl); 2024 Apr 20; 137(8):949-958. PubMed ID: 37690993
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.